




164164

CLAIMS



G00002

1. A compound of formula (I):



5


(I)

wherein R is C₁₋₄ alkyl or C₁₋₄ haloalkyl.

2. 4-Aminomethyl-3-methoxyiminopyrrolidinium dimethanesulfonate.
3. A compound of formula (I) as claimed in claim 1 which is 4-aminomethyl-3-methoxyiminopyrrolidinium dimethanesulfonate.
4. A process for the production of a compound of formula (I) as defined in claim 1 or 3 which comprises reaction of a compound of formula (II):

10

15



(II)

with methanesulfonic acid,

20

wherein R is as defined for formula (I); and P₁ and P₂, which may be the same or different, are amino protecting groups.

25

30


5. The process according to claim 4 wherein P₁ and P₂ are both t-butyloxycarbonyl.
6. The process according to claim 4 or 5 wherein the amount of methanesulfonic acid used to effect the deprotection of the compound of formula (II) is 2 to 4 equivalents.
7. The process according to any one of claims 4 to 6 wherein the reaction is carried out at a temperature between about 10°C and about 50°C.
8. The process according to any one of claims 4 to 7 wherein the reaction is carried

out in a solvent being methanol, ethanol, isopropanol, n-propanol, dichloromethane, acetonitrile, acetone, methyl iso-butyl ketone, DME, THF, tert-butylmethyl ether, dioxane, ethyl acetate, or a mixture of any of these.

9. The process according to any one of claims 4 to 7 wherein the reaction is carried out in a solvent being methanol.


10. The process according to any one of claims 4 to 9 wherein the reaction is carried out in a solvent, and wherein from about 4 equivalents to 10 equivalents by volume of the solvent are used.

11. A process for the production of a compound of formula (III), or a pharmaceutically acceptable salt and/or hydrate thereof:



(III)

wherein R is as defined for formula (I) in claim 1 or 3, which comprises reaction of a compound of formula (I) as defined in claim 1 or 3, with a compound of formula (IV):



(IV)

wherein X is a leaving group; and optionally forming a pharmaceutically acceptable salt and/or hydrate thereof.

12. The process according to claim 11 wherein the reaction of the compound of formula (I) and the compound of formula (IV) is conducted in a solvent in the presence of a base.

13. The process according to claim 11 or 12 wherein the compound of formula

(III) is (R,S)-7-(3-aminomethyl-4-*syn*-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate or a hydrate thereof.